Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Claritev Corp filings on SEC EDGAR ↗
Claritev Insider Ares Management LLC Buys $390K of Stock
Ares Management LLC bought 13,587 shares of Claritev Corp at $28.73 a share, worth $390K in total on Nov 11, 2026. Shares held after the trade: 2,063,105 (+0.7%).
Claritev Pres., CEO & Executive Chair Travis Dalton Buys $150K of Stock
Travis Dalton, Pres., CEO & Executive Chair, bought 5,110 shares of Claritev Corp at $29.34 a share, worth $150K in total on Nov 11, 2026. Shares held after the trade: 57,432 (+9.8%).
Claritev Insider Michael Stuart Klein Sells $1.82M of Stock
Michael Stuart Klein sold 65,567 shares of Claritev Corp at $23.75 to $28.60 a share (average $27.72) in 3 transactions, worth $1.82M in total between Nov 10, 2026 and Nov 12, 2026. Shares held after the trade: 195,490 (-9.3%).
Claritev Insider Ares Management LLC Buys $2.94M of Stock
Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).
Claritev Insider Ares Management LLC Buys $2.94M of Stock
Ares Management LLC bought 115,579 shares of Claritev Corp at $24.42 to $26.14 a share (average $25.40) in 2 transactions, worth $2.94M in total between Nov 9, 2026 and Nov 10, 2026. Shares held after the trade: 2,049,518 (+3.3%).
Claritev Corporation reported a net loss of $61.8 million for the third quarter of 2026, an improvement from the $69.8 million loss in the prior year period, driven by a 9% increase in revenues to $268.3 million. Despite higher operating income, the company remains heavily burdened by $100.9 million in quarterly interest expense and carries a total shareholders' deficit of $339.9 million.
Claritev Corp's management presented a purely philosophical and aspirational vision for healthcare transparency without providing any financial metrics, performance data, or quantitative guidance.
Claritev Corporation reported Q3 2026 revenues of $268.3 million, a 9.1% increase year-over-year, despite a net loss of $61.8 million. The company raised its full-year 2026 revenue guidance to a range of $1.038 billion to $1.043 billion and introduced a preliminary 2027 revenue outlook of $1.1 billion.
Term
Q3 2026
“Our teams executed with focus, our clients responded to the value we are bringing them, and results came in ahead of our expectations. What stands out most to me is the breadth of what our team is delivering: growth across our solutions and our verticals, and an innovation engine, including dozens of AI agents already at work inside our workflows, that is raising the bar for how we serve our clients.”
Travis Dalton, Chairman, CEO and President of Claritev
“Our third-quarter performance reinforces our belief in the trajectory of the business and gives us the conviction to raise our current full-year outlook and introduce an early view of 2027. It’s clear, our diversification strategy is working and delivering strong financial results. We are now running approximately a year ahead of our March 2026 Investor Day plan, with preliminary 2027 revenue expectations of $1.1 billion.”
Claritev Insider Ares Management LLC Buys $1.68M of Stock
Ares Management LLC bought 70,834 shares of Claritev Corp at $23.53 to $24.07 a share (average $23.69) in 2 transactions, worth $1.68M in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 1,933,939 (+1.1%).
Claritev Insider Ares Management LLC Buys $1.68M of Stock
Ares Management LLC bought 70,834 shares of Claritev Corp at $23.53 to $24.07 a share (average $23.69) in 2 transactions, worth $1.68M in total between Oct 23, 2026 and Oct 26, 2026. Shares held after the trade: 1,933,939 (+1.1%).
Tiffani Misencik, SVP, Chief Growth Officer, sold 5,812 shares of Claritev Corp at $23.81 a share, worth $138K in total on Oct 15, 2026. Shares held after the trade: 107,917 (-5.1%).
Claritev Corporation has appointed Jennifer Main to its Board of Directors, effective October 15, 2026, increasing the board size from 11 to 12 members. Ms. Main, who currently serves as CFO of RealMDai and Overture Life and previously served as COO of the Centers for Medicare & Medicaid Services (CMS), will serve as a Class II director and a member of the Audit Committee.